Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen
We retrospectively analyzed 48 CNS lymphoma patients who received HDC/ASCT using TBC conditioning. We found a 2-year PFS and OS rate of 80.5% and 80.1%, respectively. Toxicities included nausea/vomiting, diarrhea, mucositis, and febrile neutropenia. Treatment-related mortality was 8.3% in the first 100 days post-transplant. This data supports the use of consolidative ASCT in PCNSL and secondary CNS lymphoma patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Patricia A. Young, Daria Gaut, Davis K. Kimaiyo, Jonathan Grotts, Tahmineh Romero, John Chute, Gary Schiller, Sven de Vos, Herbert A. Eradat, John Timmerman Tags: Original Study Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Primary CNS Lymphoma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants